

Research Review™ SPEAKER SERIES

XLH: Management from paediatrics through transition and into adult life

Making Education Easy

2020

About the speakers



Dr Peter Simm

Paediatric Endocrinologist

The Royal Children's Hospital, VIC, and Murdoch Children's Research Institute and Dept of Paediatrics, University of Melbourne, VIC



Prof Richard Prince

Consultant Endocrinologist

Hollywood Medical Centre, and The University of Western Australia, WA



A/Prof Benjamin Wheeler

Paediatric Endocrinologist

Southern District Health Board, NZ, and Co-Director NZ Paediatric Surveillance Unit, NZ



Prof Craig Munns

Paediatric Endocrinologist

The Children's Hospital at Westmead, NSW, and University of Sydney, NSW



Claim CPD/CME points [Click here](#) for more info.



This review is a summary of several presentations given at a Kyowa Kirin-sponsored meeting which was live-streamed as part of this year's ANZBMS Virtual Scientific Meeting. The panel of experts, which was chaired by Professor Craig Munns, used a combined bench to bedside approach and case-based format to illustrate the differential diagnosis of patients with X-linked hypophosphatemic rickets (XLH) from other conditions that can cause hypophosphatemia. The experts also reviewed the role of FGF23 in the underlying pathophysiology of the disease and discussed how to manage patients in the transition from child to adult. Several research efforts to improve the identification and lifelong management of XLH patients were also presented.

Paediatric XLH: Diagnosis and management

Dr Peter Simm

Fictional case study - Part 1

Diagnosis & initial management

Presentation

- Female
- 3rd child to non-consanguineous parents
- Normal birth weight and early development, walked at 15 months
- Leg bowing noted from 16 months and progressing
- Other evidence of rickets included frontal bossing and flaring at wrists

Investigations

- X-ray for bone age
- Labs (ALP, phosphate, vitamin D, PTH, FGF23, urine tubular loss, TmP/GFR)
- Genetics (PHEX)

Diagnosis

- X-Linked hypophosphatemic rickets (XLH)

Management

- Doses (starting low and building up to avoid gastrointestinal intolerance)
- Phosphate 20-60 mg/kg/day
- Calcitriol 20-40 ng/kg/day
- Allied health input – multidisciplinary care sought including early involvement of physiotherapist and occupational therapist

8 years of age

- Has had 5 years of phosphate/calcitriol
- Growth is tracking on the 3rd centile (mid parental height 75th centile)
- Ongoing bowing with an 8 cm intercondylar gap; orthopaedics is considering guided growth (use of 8-plates at condyles), trying to defer osteotomies until skeletal maturation
- Fasting serum phosphate levels remain 0.8-0.9 mmol/L (reference range 0.9-2.0 mmol/L for 4 to <15 years old)
- ALP has remained 400-500 U/L (within reference range)
- Nephrocalcinosis is present but stable
- Persistent mild rickets evident on bone age X-rays
- Feels left out compared with peers, less able to participate in activity, and pain is a significant limiting factor

18 years of age

- Has been non-compliant with oral therapy for much of adolescence
- ALP now 300 (within reference range)
- Fasting phosphate levels remain at 0.8-0.9 mmol/L
- Nephrocalcinosis did not progress but is still evident
- Height is 167 cm (mid parental height was 180 cm), epiphyses fused
- Has pain with activity so minimises strenuous activity, even walking is limited
- Time for transition to adult care

Pathophysiology of XLH & the role of FGF23

While the gut plays a role in the absorption of phosphate, the kidney is the primary organ for phosphate metabolism. Approximately 90–95% of phosphate is resorbed by the kidney, predominantly via fibroblast growth factor 23 (FGF23) and parathyroid hormone (PTH) mechanisms. FGF23 lowers serum phosphate by decreasing phosphate reabsorption and decreasing the hydroxylation of 25OH Vitamin D which in turn decreases phosphate absorption (Figure 1).




Figure 1. The pathophysiology of FGF23-related hypophosphatemia.

The most common form of hypophosphatemia is X-linked hypophosphatemia, which is due to inactivating mutations in the *PHEX* gene and occurs at a rate of 1:20,000 to 1:25,000.^{1,2} From a biochemistry perspective, X-linked hypophosphatemia is characterised by low serum phosphate, elevated alkaline phosphatase (ALP), reduced TmP/GFR, normal or mildly elevated PTH, normal serum calcium, normal 25OH vitamin D, low 1,25(OH)₂ vitamin D and elevated FGF23.^{1,4}

Causes, management and treatment outcomes

Hypophosphatemic rickets can be FGF23-mediated and non-FGF23 mediated. It has a variable phenotype in children, with symptoms such as rickets, delayed walking, limb bowing and bone pain (Table 1).

<ul style="list-style-type: none"> Rickets Delayed walking/waddling gait Limb bowing (post weight bearing) Bone pain Short stature 	<ul style="list-style-type: none"> Enthesopathies (more in adults) Midface hypoplasia/frontal bossing Muscle weakness Dental problems - abscesses
---	---

It is important to investigate the cause of any phosphate loss. Because phosphate levels are variable and can change with time of day, meals, and age, the ideal approach is to perform a paired urine and serum test after an overnight fast. To document renal phosphate loss, tubular maximum resorption for phosphate (TmP/GFR) should be calculated.

Growth is a big consideration in the treatment approach. Up to 60% of children with hypophosphatemic rickets fall short of expected final heights even with therapy. Evidence suggests that commencing treatment before a child turns 1 year old can reduce orthopaedic complications and improve height outcomes.⁵

The standard therapies for hypophosphatemic rickets include:

- Phosphate replacement - regular dosing is key to overcoming reduced TmP/GFR, which rapidly increases with phosphate dosing but is back to baseline levels within 90 minutes; the recommended dose is 20–60mg/kg/day, which is best divided up to 5–7 times per day
- Calcitriol - recommended dose of 20–40 ng/kg/day to prevent secondary hyperparathyroidism; note there is no need for calcitriol for non-FGF23-mediated disorders
- Growth hormone therapy - not recommended as routine therapy due to a lack of efficacy data
- Allied health input and support from the time of diagnosis.

Treatment for hypophosphatemic rickets can have complications. Normalising serum phosphate is difficult to achieve without exacerbating other problems, and children need to be monitored (Table 2). Complications can include diarrhoea and intolerance to high phosphate doses, nephrocalcinosis, secondary/tertiary hyperparathyroidism and incomplete resolution of growth issues, pain or other skeletal changes such as bowing. In addition, children with hypophosphatemic rickets may develop lower limb deformity, with around two thirds requiring some operative intervention. They can also develop dental abscesses, craniosynostosis, osteotomies, Arnold/Chiari malformations and hearing issues.

Table 2. Suggested monitoring plan for children with hypophosphatemic rickets

3-monthly	6-monthly	Yearly	As needed
<ul style="list-style-type: none"> Growth Se ALP Se PTH Urine Ca/Cr ratio 	<ul style="list-style-type: none"> Dental review 	<ul style="list-style-type: none"> Renal ultrasound Bone age 6-minute walk test (over age 5) 	<ul style="list-style-type: none"> Ongoing multidisciplinary therapy (e.g. physiotherapy and occupational therapy) Orthopaedic input if significant bowing Low threshold for MRI if headaches, persistent vomiting or abnormal skull shape

Ca/Cr = calcium/creatinine; MRI = magnetic resonance imaging; Se ALP = serum alkaline phosphatase; Se PTH = serum parathyroid hormone

There are challenges associated with the treatments for hypophosphatemic rickets. Conventional therapy is difficult to comply with given the frequency of dosing required and the possible side effects, and most patients with residual deformities will require intervention and have reduced final height.

Genetic disorders of phosphate metabolism: How to manage the transition to optimal lifelong adult care

Professor Richard Prince

Fictional case study - Part 2

Outcomes (32 years of age)

Presentation

- Has had a stress fracture right hip which was pinned
- Underwent a total right knee replacement
- Had non-healing stress fractures in the right and left midshaft femora
- Suffers from anxiety and depression
- Now has right thigh pain

Investigations

- There is an oblique band of moderately intense uptake of tracer in the right proximal femoral shaft in the subtrochanteric region; on SPECT/CT imaging this is at the anterior cortex of the proximal femur and has an oblique orientation
- In the left proximal femur, there is a further less intense focus of uptake involving the medial cortex; no definite cortical abnormality can be seen on the correlative slices of the low dose CT study
- Biochemistry - Fasting phosphate 0.87 mmol/L (ref range 0.75 - 1.5), TmP/GFR 0.63 mmol/L GF (ref range 0.75 - 1.35), ALP 167 U/L (ref range 30–110), eGFR, PTH and 25-OH Vit D within reference range,

Management

- Heal insufficiency fractures with pain control and optimisation of fracture callus mineralisation through increased dietary phosphate, continued calcitriol and optimised vitamin D
- Long-term management to prevent excessive osteomalacia and reduce nephrocalcinosis risk
- Liaise with expert dentist
- Review joint status

Diagnosing XLH in adults

Some patients with XLH will be diagnosed for the first time as an adult. A recently reported study suggests that approximately 11% of XLH cases are diagnosed after the age of 18.⁶ When diagnosing XLH in adults it is important to:

- Manage vitamin D deficiency
- Exclude hyperparathyroidism-induced phosphate wasting
- Exclude Fanconi type syndromes
- Determine whether there is FGF23 dependent disease.

Patients with genetic hypophosphatemic osteomalacia have a range of clinical and functional problems (Table 3). A study examining the lifelong impact of XLH found recurrent fractures occurred most often in the femur, feet, and tibia/fibula.⁷ XLH can also result in osteoarthritis, osteophytes and enthesophytes, which in turn can affect biomechanical function.⁸ Most (almost 100%) of patients with XLH have dental abnormalities, specifically enamel defects.⁹

Table 3. Clinical and functional problems in patients with genetic hypophosphatemic osteomalacia

Structural bone abnormalities

- Short stature
- Osteomalacia / hyperparathyroidism
- Fractures

Structural joint abnormalities

- Enthesopathy
- Joint stiffness
- Spinal stenosis

Muscle weakness

Dental abnormalities

- Dental abscess

Renal complications

Hearing loss and tinnitus

Functional abnormalities

- Pain
- Ambulation difficulties
- Fatigue
- Loss of balance

Managing adults with XLH

XLH is a burdensome disease, causing bone pain and joint pain in both adults and children.⁷ When considering metabolic treatment for adult patients with XLH, several issues should be considered. These include the reasons for the use of calcitriol and phosphate e.g. stress and completed fracture healing, tooth abscess healing, and/or the prevention of severe osteomalacia based on normalising ALP. Physicians should also consider how to prevent hyperparathyroidism and renal failure.

The patient perspective is also an important consideration. Two surveys conducted in 286 adult patients found:¹⁰

- Mobility and chronic pain were the symptoms that had the biggest impact on quality of life
- 35% of responders indicated that hypophosphatemia had a severe impact on daily life
- Almost half of the patients (44%) used over the counter medications to relieve pain, and 18% used opioid medications
- The impact of the disease increased over time, having additional impacts for 84% of responders.

National guidelines

The Australian and New Zealand Hypophosphatemic Management Working Party is an initiative of ANZBMS which aims to improve the health management of hypophosphatemic rickets in adults by developing agreed national guidelines. The guidelines will consider a range of issues in the management of patients, including the need for a consulting expert to manage hypophosphatemic rickets, how to transition from paediatric to adult care, what optimal adult XLH management looks like, and the role of allied health professionals. This is particularly relevant given the polling of the ANZBMS audience showed there were differing views on whether to treat adult XLH patients, when to treat them, and what to treat them with (phosphate monotherapy, calcitriol monotherapy or combined phosphate and calcitriol).

Current Australian & New Zealand studies

Studies 1 & 2: Australian & New Zealand paediatric XLH prevalence surveys

Associate Professor Benjamin Wheeler

Background: The Australian and New Zealand Paediatric Surveillance units (APSU and NZPSU) are well placed to investigate rare paediatric diseases such as XLH given their involvement in monitoring and surveillance in both countries.

Objectives: To estimate the prevalence of XLH in Australia & New Zealand, and to describe the cases in terms of demographics, family history, biochemistry, clinical features, and treatments.

Methods: Observational survey study where one-off XLH report cards will be sent to all paediatric specialists in Australia and New Zealand (mirrored). The report cards are to be completed for children with:

- Radiological evidence of rickets, ALP values above the normal age and gender-matched limits of the local laboratory range, and serum phosphate values below the normal limits of the local laboratory range, and
- Either a pathogenic mutation in the *PHEX* gene, and/or FGF23 levels above the limits of the local laboratory range, and/or family history that supports X-linked inheritance.

The XLH report card will also be sent to physicians of adult patients to capture data on adults with XLH.

Study 3: Clinical registry to evaluate treatment outcomes in paediatric X-linked hypophosphatemic rickets (XLH) in Australia

Professor Craig Munns

Objective: To establish a REDCap electronic registry that captures longitudinal clinical data and treatment outcomes in Australian children with XLH.

Methods: A prospective, longitudinal, patient registry study consisting of a pilot study of approximately 30 paediatric XLH patients currently being managed at the Children's Hospital Westmead, followed by an extension study consisting of approximately 250 paediatric patients. The study will initially run for 18 months with the potential for long-term follow up (>10 years). Clinical, biochemical, radiological, and quality of life data will be collected. Eligible patients will include children with:

- Radiological evidence of rickets, ALP values above the normal age and gender-matched limits of the local laboratory range and serum phosphate values below the normal limits of the local laboratory range, and
- Either a pathogenic mutation in the *PHEX* gene, and/or FGF23 levels above the limits of the local laboratory range, and/or family history that supports X-linked inheritance.

Take home messages

- Treating XLH in children can be challenging and close monitoring is required; the standard therapies for XLH in children include phosphate replacement and calcitriol along with involvement from allied health professionals.
- Treating adults with XLH involves thinking about the reasons for the use of calcitriol and phosphate, prevention of hyperparathyroidism and renal failure and consideration of the patient perspective.
- There is a lot of variability in how adults with XLH are managed, highlighting a need for national guidelines and a better approach to the transition from paediatric to adult patients.
- Studies being conducted in Australia and New Zealand will provide insight into the prevalence, characteristics and treatment outcomes of XLH patients.

Research Review™ SPEAKER SERIES

XLH: Management from paediatrics through transition and into adult life

References

1. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. *Nat Genet.* 1995;11(2):130-6.
2. Skrinar A, et al. The lifelong impact of X-linked hypophosphatemia: Results from a burden of disease survey. *J Endocr Soc.* 2019;3(7):1321-34.
3. Imel EA, et al. FGF23, hypophosphatemia, and emerging treatments. *JBMR Plus.* 2019;3(8):e10190.
4. Imel EA, et al. Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations. *J Clin Endocrinol Metab.* 2010;95(4):1846-50.
5. Quinlan C, et al. Growth in PHEX-associated X-linked hypophosphatemic rickets: the importance of early treatment. *Pediatr Nephrol.* 2012;27(4):581-8.
6. Emma F, et al. X-linked hypophosphatemic rickets: an Italian experts' opinion survey. *Ital J Pediatr.* 2019;45(1):67.
7. Skrinar A, et al. The lifelong impact of X-linked hypophosphatemia: Results from a burden of disease survey. *J Endocr Soc.* 2019;3(7):1321-34.
8. Steele A, et al. Osteoarthritis, osteophytes, and enthesophytes affect biomechanical function in adults with X-linked hypophosphatemia. *J Clin Endocrinol Metab.* 2020;105(4):dgaa064.
9. Chaussain-Miller C, et al. Dental abnormalities in patients with familial hypophosphatemic vitamin D-resistant rickets: prevention by early treatment with 1-hydroxyvitamin D. *J Pediatr.* 2003;142(3):324-31.
10. XLH Network. Voice of the Patient Report. July 2019. Available at: https://www.xlhnetwork.org/application/files/5515/9317/2550/VOP_Report.pdf. Accessed October 2020.



Kyowa KIRIN

Developing Revolutionary Treatments
Through Leading-Edge Biotechnology

At Kyowa Kirin we pioneer new treatments resulting in stronger bonds between science, healthcare professionals, patients and families all driven by improved health outcomes.

©2019 Kyowa Kirin Limited. All rights reserved. Kyowa Kirin Australia Pty Ltd, 68 York Street, Sydney. August 2019. KKAU-COR-1908061

Company Commissioned Article

This article has been commissioned by Kyowa Kirin Australia Pty Ltd. The content is entirely independent and based on published studies and the authors' opinions. It may not reflect the views of Kyowa Kirin. Please consult the full Australian Product Information for any product mentioned in this review via the TGA website <https://www.ebs.tga.gov.au> before prescribing. Treatment decisions based on these data are the full responsibility of the prescribing physician.

Australian Research Review subscribers can claim CPD/CME points for time spent reading our reviews from a wide range of local medical and nursing colleges. Find out more on our [CPD page](#).

Speaker Series are prepared with an independent commentary from relevant specialists. To become a reviewer please email geoff@researchreview.com.au.

Research Review Australia Pty Ltd is an independent Australian publisher. Research Review receives funding from a variety of sources including Government depts., health product companies, insurers and other organisations with an interest in health. Journal content is created independently of sponsor companies with assistance from leading local specialists. **Privacy Policy:** Research Review will record your email details on a secure database and will not release them to anyone without your prior approval. Research Review and you have the right to inspect, update or delete your details at any time. **Disclaimer:** This publication is not intended as a replacement for regular medical education but to assist in the process. The reviews are a summarised interpretation of the published study and reflect the opinion of the writer rather than those of the research group or scientific journal. It is suggested readers review the full trial data before forming a final conclusion on its merits.

Research Review publications are intended for Australian health professionals.

